Characteristics of children with and without event following treatment for ALL
| . | No. subjects and frequency (%) . | |||||
|---|---|---|---|---|---|---|
| Event . | Nonevent . | P* . | P† . | |||
| Sex | .7 | .2 | ||||
| Female | 15 | (42.9) | 77 | (45.6) | — | — |
| Male | 20 | (57.1) | 92 | (54.4) | — | — |
| Age, y | <.001 | .02 | ||||
| <1 | 4 | (11.4) | 3 | (1.8) | — | — |
| 1-10 | 23 | (65.7) | 136 | (80.5) | — | — |
| >10 | 8 | (22.9) | 30 | (17.8) | — | — |
| WBC, ×109/L | .2 | .02 | ||||
| <50 | 23 | (71.9) | 140 | (82.8) | — | — |
| >50 | 9 | (28.1) | 29 | (17.2) | — | — |
| Immunophenotype | .2 | .1 | ||||
| T | 2 | (5.7) | 20 | (12.0) | — | — |
| B | 33 | (94.3) | 146 | (88.0) | — | — |
| DNA index‡ | .5 | .5 | ||||
| <1.16 | 23 | (82.1) | 132 | (87.4) | — | — |
| >1.16 | 5 | (17.9) | 19 | (12.6) | — | — |
| Risk groups | <.01 | .05 | ||||
| Standard | 14 | (40.0) | 65 | (38.5) | — | — |
| High | 15 | (42.9) | 98 | (58.0) | — | — |
| Very high | 6 | (17.1) | 6 | (3.6) | — | — |
| Treatment protocol | .4 | .04 | ||||
| 87–01 | 6 | (17.1) | 12 | (7.1) | — | — |
| 91–01 | 15 | (42.9) | 55 | (32.5) | — | — |
| 95–01 | 14 | (40.0) | 102 | (60.4) | — | — |
| . | No. subjects and frequency (%) . | |||||
|---|---|---|---|---|---|---|
| Event . | Nonevent . | P* . | P† . | |||
| Sex | .7 | .2 | ||||
| Female | 15 | (42.9) | 77 | (45.6) | — | — |
| Male | 20 | (57.1) | 92 | (54.4) | — | — |
| Age, y | <.001 | .02 | ||||
| <1 | 4 | (11.4) | 3 | (1.8) | — | — |
| 1-10 | 23 | (65.7) | 136 | (80.5) | — | — |
| >10 | 8 | (22.9) | 30 | (17.8) | — | — |
| WBC, ×109/L | .2 | .02 | ||||
| <50 | 23 | (71.9) | 140 | (82.8) | — | — |
| >50 | 9 | (28.1) | 29 | (17.2) | — | — |
| Immunophenotype | .2 | .1 | ||||
| T | 2 | (5.7) | 20 | (12.0) | — | — |
| B | 33 | (94.3) | 146 | (88.0) | — | — |
| DNA index‡ | .5 | .5 | ||||
| <1.16 | 23 | (82.1) | 132 | (87.4) | — | — |
| >1.16 | 5 | (17.9) | 19 | (12.6) | — | — |
| Risk groups | <.01 | .05 | ||||
| Standard | 14 | (40.0) | 65 | (38.5) | — | — |
| High | 15 | (42.9) | 98 | (58.0) | — | — |
| Very high | 6 | (17.1) | 6 | (3.6) | — | — |
| Treatment protocol | .4 | .04 | ||||
| 87–01 | 6 | (17.1) | 12 | (7.1) | — | — |
| 91–01 | 15 | (42.9) | 55 | (32.5) | — | — |
| 95–01 | 14 | (40.0) | 102 | (60.4) | — | — |
An event is described as a relapse or a fatal outcome.
†Tests of significance were derived from Kaplan-Meier and Cox regression analysis, respectively.
Ratio of DNA content of leukemia to normal cells. Factors shown here to influence risk of event were considered as confounding variables in a multivariate model built to assess the role of RFC1 on ALL outcome. In the analysis, categories associated with lower risk for relapse were considered as references for the analysis (age range between 1 and 10 years, WBC count lower than 50 × 109/L, B-cell type, standard risk group, and most recent treatment protocol).